Myeloid Leukemia, Chronic Clinical Trial
Official title:
A Randomized, Multicenter, Open-label Phase II Study of Dasatinib (BMS-354825) Administered Orally at a Dose of 50mg Twice Daily or 100mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Imatinib
The objective is to evaluate the cytogenetic response to Dasatinib (BMS-354825) administered for 24 weeks in subjects with Imatinib resistant or intolerant chronic phase chronic myeloid leukemia (CML) once daily (QD) or twice daily. (BID)
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00114959 -
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
|
Phase 2 | |
| Terminated |
NCT02086487 -
Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy
|
Phase 4 | |
| Recruiting |
NCT00445822 -
Registration of Children With CML and Treatment With Imatinib
|
N/A | |
| Completed |
NCT00478985 -
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
|
N/A | |
| Terminated |
NCT02543749 -
DC Vaccination in CML
|
Phase 1/Phase 2 | |
| Terminated |
NCT00210119 -
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response
|
Phase 2 | |
| Completed |
NCT02222272 -
Effect of 2nd Gen TKI in CML
|
||
| Completed |
NCT01660607 -
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
|
Phase 1/Phase 2 | |
| Completed |
NCT02890784 -
Dasatinib Holiday for Improved Tolerability
|
Phase 3 | |
| Completed |
NCT00481247 -
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
|
Phase 3 |